Suppliers and packagers for generic pharmaceutical drug: POLIDOCANOL

POLIDOCANOL

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Chemisch Fbrk Krsslr	ASCLERA	polidocanol	SOLUTION;INTRAVENOUS	021201	NDA	Methapharm, Inc	67850-140-05	2 mL in 1 AMPULE (67850-140-05)	2010-06-01
Chemisch Fbrk Krsslr	ASCLERA	polidocanol	SOLUTION;INTRAVENOUS	021201	NDA	Methapharm, Inc	67850-141-05	2 mL in 1 AMPULE (67850-141-05)	2010-06-01
Provensis	VARITHENA	polidocanol	SOLUTION;INTRAVENOUS	205098	NDA	Biocompatibles, Inc.	60635-118-01	1 POUCH in 1 CARTON (60635-118-01) / 1 KIT in 1 POUCH * 18 mL in 1 CANISTER (60635-018-01) * 303 mL in 1 CANISTER	2014-07-10
Provensis	VARITHENA	polidocanol	SOLUTION;INTRAVENOUS	205098	NDA	Biocompatibles, Inc.	60635-133-01	1 CARTON in 1 PACKAGE (60635-133-01) / 1 POUCH in 1 CARTON / 1 KIT in 1 POUCH * 18 mL in 1 CANISTER (60635-018-01) * 303 mL in 1 CANISTER	2013-11-25

POLIDOCANOL DRUG SUPPLIERS AND PATENT LANDSCAPE

Last updated: February 19, 2026

This report analyzes the current landscape of Polidocanol drug suppliers, focusing on key manufacturers, their production capabilities, and the patent protection influencing market dynamics. Polidocanol is an anionic surfactant with sclerosant properties, primarily used in the treatment of varicose veins and hemorrhoids.

WHAT ARE THE PRIMARY USES OF POLIDOCANOL?

Polidocanol is utilized clinically for its sclerosing properties. It causes inflammation of the vascular endothelium, leading to thrombosis and fibrosis, thereby obliterating the target vessel.

• Varicose Veins: Polidocanol is administered via injection to close off diseased veins, redirecting blood flow to healthier vessels. This is a common treatment for superficial varicose veins and spider veins.
• Hemorrhoids: Injected Polidocanol can also be used to treat internal hemorrhoids by inducing fibrosis and shrinking the hemorrhoidal tissue.
• Anal Fissures: In some applications, Polidocanol is explored for its potential to promote healing in anal fissures.

WHO ARE THE MAJOR POLIDOCANOL ACTIVE PHARMACEUTICAL INGREDIENT (API) MANUFACTURERS?

Several companies globally manufacture Polidocanol API. Production typically requires specialized chemical synthesis and stringent quality control to meet pharmaceutical standards.

• Chemische Fabrik Kreussler & Co. GmbH: This German pharmaceutical company is a significant producer of Polidocanol and is well-established in the sclerosant market. They are known for their proprietary formulations and manufacturing expertise.
• B. Braun Melsungen AG: While primarily a manufacturer of finished drug products utilizing Polidocanol, B. Braun also engages in API production or secures its supply from specialized manufacturers. Their extensive distribution network supports global access.
• Recordati S.p.A.: This international pharmaceutical group is involved in the production and commercialization of Polidocanol-based formulations. Their vertical integration may include API sourcing or manufacturing.
• Specialty Chemical Manufacturers: A number of smaller, specialized chemical synthesis companies may produce Polidocanol API on a contract basis or for specific regional markets. These entities often operate under strict cGMP (current Good Manufacturing Practices) guidelines.

Table 1 outlines key characteristics of prominent Polidocanol API manufacturers.

Manufacturer	Country of Origin	Primary Business Model	Notes
Chemische Fabrik Kreussler & Co. GmbH	Germany	API and Finished Product Manufacturing	Strong focus on sclerosant products, established market presence.
B. Braun Melsungen AG	Germany	Medical Devices and Pharmaceutical Products	Global reach, may source API or have internal production capabilities.
Recordati S.p.A.	Italy	Pharmaceutical Research, Development, and Marketing	Operates in multiple therapeutic areas, including vascular treatments.
Selected Specialty Chemical Synthesizers	Various	Contract Manufacturing, API Supply	Adhere to pharmaceutical quality standards, cater to specific needs.

WHAT IS THE PATENT LANDSCAPE FOR POLIDOCANOL FORMULATIONS AND USES?

The patent landscape for Polidocanol primarily focuses on novel formulations, improved delivery systems, and specific therapeutic applications rather than the Polidocanol molecule itself, which is long-established. Patents protect the innovative aspects of how Polidocanol is administered or its enhanced efficacy in treating specific conditions.

ARE THERE PATENTS ON POLIDOCANOL MANUFACTURING PROCESSES?

While the basic synthesis of Polidocanol is part of the public domain, patents can exist for optimized or novel manufacturing processes that offer advantages such as higher purity, increased yield, reduced environmental impact, or lower production costs. Identifying these specific process patents requires detailed patent searching using chemical structure and process-related keywords. The key is often in the specific steps, catalysts, or purification techniques employed.

WHAT TYPES OF PATENTS PROTECT POLIDOCANOL DRUG PRODUCTS?

Patents for Polidocanol drug products typically fall into several categories:

• Formulation Patents: These patents cover specific compositions of Polidocanol. This can include:
  • Concentration: Novel or optimized concentrations for particular indications.
  • Excipients: Inclusion of specific inactive ingredients (e.g., buffers, stabilizers, local anesthetics like lidocaine) that improve solubility, stability, patient comfort, or reduce side effects.
  • Delivery Systems: Encapsulation technologies or specialized vehicles designed for sustained release or targeted delivery.
• Method of Treatment Patents: These patents claim the use of Polidocanol for treating a specific medical condition. This is particularly relevant if a new indication for Polidocanol is discovered or if a new method of applying it to an existing indication provides significant clinical benefit.
• Combination Therapy Patents: Patents may cover the use of Polidocanol in combination with other active pharmaceutical ingredients for synergistic effects or improved treatment outcomes.
• Dosage Form Patents: Patents related to specific dosage forms, such as improved injectables with specialized needle or syringe designs for enhanced administration.

WHAT IS THE TIMELINE OF KEY POLIDOCANOL PATENT FILINGS AND EXPIRATIONS?

Detailed analysis of patent filings and expirations requires access to specialized patent databases. However, the general trend is that patents on the original Polidocanol molecule and its foundational uses have long expired. Newer patents focus on specific product innovations.

• Early Patents: Foundational patents related to the chemical synthesis and initial therapeutic uses of Polidocanol would have expired decades ago. For instance, its use as a sclerosant dates back to the mid-20th century.
• Modern Patents: Patents filed in the last 10-20 years are more likely to be related to:
  • Formulations with Lidocaine: A common innovation is the combination of Polidocanol with a local anesthetic like lidocaine to reduce pain during injection. Patents related to specific ratios or synergistic effects of such combinations are relevant. For example, patents may cover the claim "A pharmaceutical composition comprising Polidocanol and lidocaine for the treatment of varicose veins."
  • Specific Injectable Devices: Improvements to the injection process, such as microfoam formulations or specialized applicators, may be patented.
  • New Indications: While less common for an established drug, research into new therapeutic areas could lead to method-of-treatment patents.

A representative example of a patent type is the one claiming a Polidocanol and lidocaine composition. Such patents, if granted, typically have a term of 20 years from the filing date, subject to potential extensions based on regulatory review periods (e.g., Patent Term Extension in the US). For a patent filed in, say, 2010, the basic term would expire in 2030.

WHICH COMPANIES HOLD KEY PATENTS FOR POLIDOCANOL FORMULATIONS?

Several pharmaceutical companies and research institutions have secured patents related to Polidocanol formulations. Identifying the specific patent holders requires a comprehensive patent search. However, companies actively marketing Polidocanol-based products are primary candidates.

• Chemische Fabrik Kreussler & Co. GmbH: As a historical leader in Polidocanol sclerosants, Kreussler likely holds patents for its proprietary formulations, such as Aethoxysklerol® or Asclera®. Their patents would focus on the specific compositions and manufacturing methods that distinguish their products.
• Merz Pharma GmbH & Co. KGaA: Merz acquired the rights to certain Polidocanol products in specific regions, and thus may hold or license patents related to these formulations.
• Leo Pharma A/S: Leo Pharma has been involved in dermatology and has patents related to various injectable therapies, potentially including Polidocanol.
• Smaller Biotechnology and Pharmaceutical Firms: Numerous smaller entities may hold patents for niche applications or improved delivery systems that they then license to larger manufacturers.

A hypothetical patent could be "US Patent No. X,XXX,XXX: Pharmaceutical composition for the treatment of venous malformations comprising polidocanol and lidocaine," filed by a company like Kreussler. Such a patent would grant the holder exclusive rights to make, use, and sell that specific composition for a defined period.

HOW DO PATENTS AFFECT THE AVAILABILITY OF POLIDOCANOL-BASED GENERICS?

Patents are the primary mechanism for protecting the commercial exclusivity of a pharmaceutical product. Their existence directly impacts the availability of generic alternatives.

• Exclusivity Period: During the patent term, the patent holder has exclusive rights to their invention. This prevents other companies from manufacturing, selling, or importing generic versions of the patented Polidocanol product.
• "Patent Cliff": When a key patent expires, the market often opens to generic competition. This can lead to a significant decrease in the price of the drug due to increased competition.
• "Evergreening": Pharmaceutical companies may employ strategies to extend patent protection beyond the original term. This can involve obtaining new patents on minor modifications to the drug, such as new formulations, delivery methods, or new uses, which can delay generic entry. For Polidocanol, this could involve patents on new combinations with other agents or enhanced drug-device combinations.
• Patent Litigation: Companies seeking to launch generics often challenge existing patents, leading to patent litigation. The outcome of these legal battles determines when generic versions can enter the market.
• Regulatory Exclusivities: In addition to patent protection, regulatory bodies may grant periods of market exclusivity for certain types of drugs (e.g., new chemical entities, orphan drugs), which can further delay generic competition. However, Polidocanol is an established compound, so these are less likely to apply to the API itself.

Example of Impact: If a patent covering a Polidocanol-Lidocaine formulation filed in 2015 expires in 2035, generic manufacturers cannot launch their versions until that expiration date (assuming no earlier successful patent challenge). Prior to this, only the innovator company and its licensees can legally sell that specific formulation.

WHAT ARE THE REGULATORY CONSIDERATIONS FOR POLIDOCANOL MANUFACTURING AND SUPPLY?

The manufacturing and supply of Polidocanol API and finished drug products are subject to stringent regulatory oversight by health authorities worldwide.

• Good Manufacturing Practices (GMP): All manufacturing facilities must adhere to cGMP standards established by agencies like the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others. GMP ensures product quality, purity, and consistency.
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. These confidential documents provide detailed information about the manufacturing process, facilities, and quality controls of the API. Drug product manufacturers can then reference these DMFs in their marketing applications.
• Marketing Authorization Applications (MAAs) / New Drug Applications (NDAs): Companies seeking to sell Polidocanol-based drugs must obtain marketing approval from relevant health authorities. This involves submitting comprehensive dossiers including data on preclinical studies, clinical trials, manufacturing, and quality control.
• Pharmacovigilance: Post-market surveillance is crucial. Manufacturers and distributors must monitor and report adverse events associated with Polidocanol products.
• Supply Chain Integrity: Ensuring the security and integrity of the supply chain, from raw material sourcing to final product distribution, is a critical regulatory concern. This includes preventing counterfeiting and ensuring proper storage and transportation conditions.

The regulatory environment necessitates robust quality management systems and comprehensive documentation from all parties involved in the Polidocanol supply chain.

HOW CAN COMPANIES SECURE RELIABLE POLIDOCANOL SUPPLY?

Securing a reliable supply of Polidocanol API and finished products requires strategic vendor management and risk mitigation.

1. Supplier Qualification:
   • Conduct thorough audits of potential API manufacturers. This includes assessing their GMP compliance, quality control systems, production capacity, regulatory history, and financial stability.
   • Review DMFs and certificates of analysis (CoAs) for consistency and adherence to specifications.
2. Dual Sourcing Strategy:
   • Identify and qualify at least two independent suppliers for critical raw materials and API. This mitigates the risk of disruption from a single supplier's production issues, natural disasters, or geopolitical instability.
3. Long-Term Contracts:
   • Establish long-term supply agreements with key vendors. These contracts should include clear terms on pricing, volume commitments, lead times, quality standards, and change control procedures.
4. Supply Chain Visibility:
   • Implement systems for real-time tracking of shipments and inventory levels. Understand the upstream supply chain of the API manufacturers to identify potential vulnerabilities.
5. Contingency Planning:
   • Develop contingency plans for supply chain disruptions. This might involve holding safety stock of API or finished products, or identifying alternative manufacturing sites.
6. Geographic Diversification:
   • Consider suppliers located in different geographic regions to reduce exposure to localized risks.
7. Intellectual Property Landscape Awareness:
   • Stay informed about the patent landscape to anticipate potential market changes and the emergence of generic competitors or new patented formulations that could impact demand.

KEY TAKEAWAYS

• Polidocanol is primarily used as a sclerosant for varicose veins and hemorrhoids.
• Key API manufacturers include Chemische Fabrik Kreussler & Co. GmbH, B. Braun Melsungen AG, and Recordati S.p.A., alongside specialized chemical synthesis firms.
• Patent protection for Polidocanol focuses on novel formulations, delivery systems, and methods of treatment, rather than the molecule itself.
• Patents significantly influence the availability of generic Polidocanol products, granting market exclusivity to innovators.
• Manufacturing and supply are governed by strict GMP regulations and require robust quality assurance.
• Companies can secure reliable supply through supplier qualification, dual sourcing, long-term contracts, and supply chain visibility.

FREQUENTLY ASKED QUESTIONS

1. What is the chemical nomenclature for Polidocanol? Polidocanol is also known as macrogol lauryl ether or polyethylene glycol monolauryl ether.
2. Are there any regulatory warnings or contraindications associated with Polidocanol use? Yes, contraindications include known hypersensitivity to Polidocanol, acute systemic diseases, inflammatory conditions of the veins, and certain types of thromboembolic conditions. Warnings may relate to potential adverse reactions such as allergic reactions, local tissue necrosis if extravasated, and thrombophlebitis.
3. Can Polidocanol be used for cosmetic vein removal? Yes, Polidocanol is widely used for the cosmetic treatment of superficial varicose veins and spider veins.
4. What is the typical shelf life of Polidocanol API? The shelf life of Polidocanol API can vary depending on the manufacturer and storage conditions but is typically several years when stored appropriately. Finished product shelf lives are determined by specific formulation stability studies.
5. How is Polidocanol synthesized at an industrial scale? Industrial synthesis typically involves the ethoxylation of lauryl alcohol with ethylene oxide, followed by purification steps to achieve pharmaceutical grade. Specific catalytic processes and purification techniques are proprietary to manufacturers.

CITATIONS

[1] European Medicines Agency. (n.d.). POLIDOCANOL. Retrieved from https://www.ema.europa.eu/en/medicines/human/EPAR/aethoxysklerol (Note: Specific EPAR content can change. This is a representative link for EMA information on the drug.) [2] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/drug-master-file-dmfs/how-use-drug-master-files-dmfs [3] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) in Manufacturing, Processing, Packing, or Holding of Drugs; General. Retrieved from https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-210 [4] Patent law resources and databases (e.g., USPTO, EPO, WIPO PATENTSCOPE). (Ongoing research).